2009
DOI: 10.1007/s10549-009-0329-x
|View full text |Cite
|
Sign up to set email alerts
|

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

Abstract: Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to what extent the better response of ER negative cancers correlates with proliferation rate. A retrospective analysis of a prospectively maintained database identified 175 neoadjuvant chemotherapy pa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

11
64
5
2

Year Published

2010
2010
2019
2019

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 108 publications
(82 citation statements)
references
References 27 publications
11
64
5
2
Order By: Relevance
“…Our findings are in line with other studies demonstrating a predictive value for HER2 expression in achieving a good response to neoadjuvant chemotherapy [27,28]. Until now, the reports concerning the predictive value of HER2 were inconsistent due to heterogeneous study populations and different systemic treatment regimens.…”
Section: Pathological Complete Response (Pcr) Following Neoadjuvant Csupporting
confidence: 91%
“…Our findings are in line with other studies demonstrating a predictive value for HER2 expression in achieving a good response to neoadjuvant chemotherapy [27,28]. Until now, the reports concerning the predictive value of HER2 were inconsistent due to heterogeneous study populations and different systemic treatment regimens.…”
Section: Pathological Complete Response (Pcr) Following Neoadjuvant Csupporting
confidence: 91%
“…Subsequent studies on breast cancer specimens from women across diverse geographies and demographics world-wide have confirmed the universality of these molecular classes and their relationship to the well-established immunohistochemistry (IHC) based clinical hormone receptor subtypes [2][3][4][5].…”
Section: Introductionmentioning
confidence: 92%
“…Thus, comparisons of pCR rates between independent trials are not sufficiently reliable to establish superior regimens because subtle differences in patient characteristics, such as ER, HER2, and grade, can have substantial impact. Unfortunately, extensive subsets of patients do not experience pCR, even with modern regimens [6,7]. Long-term survival of patients with residual tumor largely depends on its extent and baseline prognosis [8].…”
Section: Introductionmentioning
confidence: 99%